Regencell Bioscience Holdings Ltd. (RGC): Price and Financial Metrics


Regencell Bioscience Holdings Ltd. (RGC): $31.84

2.84 (+9.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RGC Stock Price Chart Interactive Chart >

Price chart for RGC

RGC Price/Volume Stats

Current price $31.84 52-week high $59.00
Prev. close $29.00 52-week low $6.00
Day low $28.57 Volume 2,336
Day high $31.96 Avg. volume 19,483
50-day MA $29.80 Dividend yield N/A
200-day MA $27.47 Market Cap 402.52M

Regencell Bioscience Holdings Ltd. (RGC) Company Bio


Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.


RGC Latest News Stream


Event/Time News Detail
Loading, please wait...

RGC Latest Social Stream


Loading social stream, please wait...

View Full RGC Social Stream

Latest RGC News From Around the Web

Below are the latest news stories about Regencell Bioscience Holdings Ltd that investors may wish to consider to help them evaluate RGC as an investment opportunity.

Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degene

Yahoo | March 1, 2022

Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate. Out of the 37 COVID-19 patients, 36 had all symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period. The trial that after taking RGC-COV19TM, 97.3% of the patients had their mild to moderate COVID-19 symptoms eliminated, save for S

Yahoo | February 17, 2022

Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

HONG KONG, February 17, 2022--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company") today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach ("EARTH") efficacy trial conducted by Regencell Bioscience Asia Limited ("Regencell Asia") of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). The results have yet to b

Yahoo | February 17, 2022

Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

HONG KONG, December 13, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the

Yahoo | December 13, 2021

Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

HONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807.

Yahoo | November 22, 2021

Read More 'RGC' Stories Here

RGC Price Returns

1-mo N/A
3-mo 48.79%
6-mo -0.03%
1-year N/A
3-year N/A
5-year N/A
YTD -0.03%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.622 seconds.